Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:CEO |
Simon Michel
|
| gptkbp:country |
gptkb:Switzerland
|
| gptkbp:focus |
diabetes care
self-injection devices |
| gptkbp:founded |
2003
|
| gptkbp:founder |
Willy Michel
|
| gptkbp:headquartersLocation |
gptkb:Burgdorf,_Switzerland
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ypsomed
|
| gptkbp:industry |
medical device
|
| gptkbp:ISIN |
CH0019396990
|
| gptkbp:market |
global
|
| gptkbp:numberOfEmployees |
over 1800
|
| gptkbp:products |
insulin pumps
injection systems |
| gptkbp:publiclyTraded |
true
|
| gptkbp:revenue |
over CHF 400 million (2022/23)
|
| gptkbp:stockExchange |
gptkb:SIX_Swiss_Exchange
|
| gptkbp:subsidiary |
none (independent)
|
| gptkbp:website |
https://www.ypsomed.com/
|
| gptkbp:bfsParent |
gptkb:insulin
|
| gptkbp:bfsLayer |
6
|